New drug aims to fix chemo side effect in breast cancer patients
NCT ID NCT07162519
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests a drug called romiplostim N01 in 68 breast cancer patients whose platelet counts dropped too low due to chemotherapy. The goal is to see if weekly injections can bring platelet levels back up within two weeks, so patients can safely continue their cancer treatment. The drug is given for up to four weeks, and dosing stops once platelets reach a safe level.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- romiplostim N01 (a platelet-boosting drug)
- What this could lead to
- If it works, this could offer a way to manage chemotherapy-induced low platelets in breast cancer patients, allowing them to continue their cancer treatment without delays.
- What could go wrong
- This is a small, early-phase study with no control group, so results may not be definitive. The drug may not work for everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?